Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of a modern biologics manufacturing facility. Aurobindo Pharma’s TheraNym Biologics launch highlights India’s push into high-capacity CDMO infrastructure, advanced bioreactor manufacturing, and global biologics outsourcing.
Pharma & Biotech

Aurobindo Pharma launches TheraNym as MSD anchor deal strengthens biologics CDMO push

Find out how Aurobindo Pharma’s TheraNym launch could reshape India’s biologics CDMO ambitions and investor sentiment.

Read More
Representative image of a modern pathology laboratory where automated PD-L1 cancer diagnostic testing is supporting faster immuno-oncology treatment decisions, reflecting Agilent Technologies’ expanded FDA approval for PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform.
Medical Devices & Diagnostics

Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis

Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.

Read More
Pharma & Biotech

Why Gilead Sciences’ Livdelzi data could reshape treatment goals in primary biliary cholangitis

Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.

Read More
Representative image of immunology research and clinical trial analysis, reflecting Johnson & Johnson’s growing nipocalimab strategy in lupus and Sjögren’s disease.
Pharma & Biotech

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!

Read More
Representative image: Biomedical researchers analyse immune-cell data in a laboratory setting, reflecting the scientific focus behind Antengene’s ATG-207 preclinical autoimmune therapy program and its CD3 and TGF-beta fusion approach.
Pharma & Biotech

Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens

Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.

Read More
Reach Surgical’s Sound Reach Swift gains CE Mark as demand rises for precision surgical tools
Medical Devices & Diagnostics

Genesis MedTech targets open surgery efficiency with Sound Reach Swift CE Mark approval

Find out how Reach Surgical’s Sound Reach Swift CE Mark approval could reshape open surgery energy device workflows in Europe.

Read More
Representative image of clinicians reviewing genomic cancer testing data and medical imaging, reflecting Veracyte’s Prosigna and Decipher ASCO 2026 results and the growing role of precision oncology diagnostics in breast cancer and prostate cancer treatment decisions.
Medical Devices & Diagnostics

Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?

Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.

Read More
Representative image: An oncologist reviews lung scan images in a modern cancer care setting, reflecting Amgen’s EU approval for Imdylltra in relapsed extensive-stage small cell lung cancer.
Pharma & Biotech

Why Amgen’s Imdylltra EU approval could reshape second-line small cell lung cancer treatment

Find out how Amgen’s Imdylltra EU approval could change relapsed small cell lung cancer treatment across Europe.

Read More
Representative image of an oncologist reviewing melanoma imaging and molecular cancer data, reflecting Natera’s Signatera collaboration with Diakonos Oncology and the growing role of ctDNA monitoring in refractory melanoma immunotherapy trials.
Medical Devices & Diagnostics

Why Natera’s Diakonos Oncology collaboration matters for ctDNA-guided cancer drug development

Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.

Read More
Representative image of scientists reviewing oncology research data in a modern biopharma laboratory, reflecting Pfizer and Innovent Biologics’ $10.5 billion collaboration and the growing race to develop antibody-drug conjugates and multispecific cancer therapies.
Pharma & Biotech

Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?

Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.

Read More